SAN FRANCISCO--(BUSINESS WIRE)--Unity (NYSE: U), the world’s leading platform of tools for creators to build and grow real-time games, apps, and experiences across multiple platforms, released the ...

Unity Technologies earned just shy of $450 million in revenue in Q2 2024, outperforming guidance and analyst expectations. While this is down 2% from its Q1 revenue of $460 million, mobile game engine ...

The stock market has closed for the day and Unity (U) has published its earnings report for Q2 2024. It shows a beat on revenue and EPS expectations, but the stock has seen dramatic shifts both north ...

This press release and the earnings call referencing this press release contain “forward-looking statements,” as that term is defined under federal securities laws, including, but not limited to, ...

Unity Software (NYSE: U) went public in September 2020 at $52 per share during the pandemic gaming boom. The company provides ...

SAN FRANCISCO--(BUSINESS WIRE)--Unity (NYSE: U), the world's leading platform of tools for creators to build and grow real-time games, apps, and experiences across multiple platforms, will demonstrate ...

Unity incurred $214 million in costs related to substantially cutting its workforce in 2024. In its annual report, the company broke it down to $15m within cost of revenue, $48m within R&D expense, ...

Unity has posted its first financial results for 2024, showing a loss of nearly $300 million for the first quarter. Despite this, the company said in a letter to shareholders that its Q1 results were ...

Unity (U) has published its earnings report for Q3 2024. In it, we see that the company behind the popular video game engine beat expectations for revenue, and took a smaller than expected loss in ...

UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...